C07H17/075

Aesculin thiodipropionic acid ester with antioxidant activity and a method of preparing the same

A compound having the following formula I: ##STR00001##
is disclosed. A method of preparing the compound of formula I is also disclosed.

CHLORINATED 4'-ALKYLUMBELLIFERYL ALPHA-D-GLUCOPYRANOSIDE AND METHOD OF ASSESSING EFFICACY OF A STERILIZATION PROCESS INCLUDING THE SAME

A chlorinated 4-alkylumbelliferyl ?-D-glucopy-ranoside represented by the structural formula (I) One of R.sup.1 and R.sup.2 is Cl and the other is H. R.sup.3 represents an alkyl group having 1 to 12 carbon atoms. A method of assessing efficacy of a sterilization process including the same is also disclosed.

CHLORINATED 4'-ALKYLUMBELLIFERYL ALPHA-D-GLUCOPYRANOSIDE AND METHOD OF ASSESSING EFFICACY OF A STERILIZATION PROCESS INCLUDING THE SAME

A chlorinated 4-alkylumbelliferyl ?-D-glucopy-ranoside represented by the structural formula (I) One of R.sup.1 and R.sup.2 is Cl and the other is H. R.sup.3 represents an alkyl group having 1 to 12 carbon atoms. A method of assessing efficacy of a sterilization process including the same is also disclosed.

NOVEL GLUCOSE DERIVATIVE, AND CELL IMAGING METHOD AND IMAGING AGENT USING SAID DERIVATIVE

Provided is a glucose derivative, which is taken into cells via a membrane sugar transport system and is represented by formula (1). Also provided are an imaging agent and an imaging method for a cell or intracellular molecule using said glucose derivative. Further provided is a method for detecting cancer cells with good accuracy using said glucose derivative and an imaging agent to be used in said method. More specifically provided are D-glucose derivatives and L-glucose derivatives in which glucose is bound to the 7-position of a fluorescent molecular group with a coumarin backbone or a quinolone backbone. Also provided are a cell imaging agent and imaging method using the derivative. A cancer cell imaging agent and imaging method using the L-glucose derivative is also provided. G is a group selected from formulas (G1)-(G4) below.

NOVEL GLUCOSE DERIVATIVE, AND CELL IMAGING METHOD AND IMAGING AGENT USING SAID DERIVATIVE

Provided is a glucose derivative, which is taken into cells via a membrane sugar transport system and is represented by formula (1). Also provided are an imaging agent and an imaging method for a cell or intracellular molecule using said glucose derivative. Further provided is a method for detecting cancer cells with good accuracy using said glucose derivative and an imaging agent to be used in said method. More specifically provided are D-glucose derivatives and L-glucose derivatives in which glucose is bound to the 7-position of a fluorescent molecular group with a coumarin backbone or a quinolone backbone. Also provided are a cell imaging agent and imaging method using the derivative. A cancer cell imaging agent and imaging method using the L-glucose derivative is also provided. G is a group selected from formulas (G1)-(G4) below.

4-METHYLUMBELLIFERONE DERIVATIVES FOR TREATMENT FOR IMMUNE MODULATION

This disclosure presents 4-MUG derivatives (e.g., 4-MUG ester prodrugs) that reduce or prevent HA synthesis. In some embodiments, the 4-MUG derivatives of the present disclosure can be used to suppress HA synthesis and curtail inflammation.

4-METHYLUMBELLIFERONE DERIVATIVES FOR TREATMENT FOR IMMUNE MODULATION

This disclosure presents 4-MUG derivatives (e.g., 4-MUG ester prodrugs) that reduce or prevent HA synthesis. In some embodiments, the 4-MUG derivatives of the present disclosure can be used to suppress HA synthesis and curtail inflammation.

Fluorinated 4′-alkylumbelliferyl a-D-glucopyranosides, biological sterilization indicators including the same and methods of using the same

A self-contained biological sterilization indicator comprises: a housing; bacterial spores comprising, and/or capable of producing, an enzyme capable of catalyzing cleavage of an enzyme substrate; and a frangible container containing a composition, wherein the composition comprises the enzyme substrate, wherein if the frangible container is broken the composition will contact the bacterial spores to form a mixture having an initial pH in the range from 6.0 to 9.0. The enzyme substrate comprises a fluorinated 4-alkylumbelliferyl -D-glucopyranoside represented by the structural formula (I) wherein one of R.sup.1 and R.sup.2 is F and the other is H, and R.sup.3 is an alkyl group having from 1 to 12 carbon atoms. A biological sterilization indicator comprising a kit containing isolated components comprising (i) bacterial spores comprising, and/or capable of producing, an enzyme capable of catalyzing cleavage of the enzyme substrate and a method of assessing efficacy of a sterilization process are also disclosed. ##STR00001##

Fluorinated 4′-alkylumbelliferyl a-D-glucopyranosides, biological sterilization indicators including the same and methods of using the same

A self-contained biological sterilization indicator comprises: a housing; bacterial spores comprising, and/or capable of producing, an enzyme capable of catalyzing cleavage of an enzyme substrate; and a frangible container containing a composition, wherein the composition comprises the enzyme substrate, wherein if the frangible container is broken the composition will contact the bacterial spores to form a mixture having an initial pH in the range from 6.0 to 9.0. The enzyme substrate comprises a fluorinated 4-alkylumbelliferyl -D-glucopyranoside represented by the structural formula (I) wherein one of R.sup.1 and R.sup.2 is F and the other is H, and R.sup.3 is an alkyl group having from 1 to 12 carbon atoms. A biological sterilization indicator comprising a kit containing isolated components comprising (i) bacterial spores comprising, and/or capable of producing, an enzyme capable of catalyzing cleavage of the enzyme substrate and a method of assessing efficacy of a sterilization process are also disclosed. ##STR00001##

Hydrolysis resistant sialic acid derivatives and methods for their use

This invention provides compound having a structure of Formulas: Furthermore, methods and uses of such compounds for covalently bonding to a sugar acceptor, to form modified protein therapeutics having reduced enzymatic hydrolysis, improved biological stability or an improved pharmacokinetic property. ##STR00001##